Commentary

Video

Dr Garcia on the Future of the MELISA Trial in Ovarian Cancer

Núria Agustí Garcia, MD, discusses the mapping of sentinel lymph nodes in early-stage ovarian cancer.

Núria Agustí Garcia, MD, postdoctoral fellow, The University of Texas MD Anderson Cancer Center, discusses an investigation into the phase 2 mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial, which is evaluating steps toward lymphadenectomy replacement in patients with ovarian cancer.

This study was exploratory in nature, aimed at determining whether the observed sentinel lymph node detection rate would support the feasibility of conducting a phase 3 trial, Garcia begins. Presently, investigators are engaged in a community-centric study using 2 tracers to assess detection rates, she says, adding that it is crucial to ensure that diagnostic accuracy remains consistent throughout these investigations. Garcia shares that she anticipates opening the multicenter study in 2024 or 2025 to validate these findings and pave the way for a successful phase 3 trial.

The technique employed in this study presents unique challenges, distinct from the methods used in cervical and endometrial cancer, she continues. Unlike in these cancers, where tracers are injected directly into the cervix, in ovarian cancer, tracers are injected intraoperatively into the surgical site, followed by further surgical procedures, Garcia reports. This underscores the need to adapt methodologies specifically for ovarian cancer rather than replicating approaches used in other gynecological cancers, according to Garcia. Additionally, although indocyanine green fluorescence is commonly used in cervical and endometrial cancers, its utility may be limited in ovarian cancer, she explains. Therefore, employing 2 tracers becomes vital, Garcia notes. In MELISA, this dual tracer approach demonstrated improved detection rates and outcomes compared with using a single tracer, as seen in other cancer types, Garcia adds.

In summary, challenges lie in tailoring sentinel lymph node detection methods to suit the unique characteristics of ovarian cancer, Garcia continues. The use of 2 tracers represents a step forward in optimizing detection rates and refining diagnostic accuracy in this disease, she notes. This iterative process of refining detection methodologies based on the MELISA study outcomes is vital for ensuring the success of future clinical trials and ultimately improving diagnostic and therapeutic approaches for patients with ovarian cancer, Garcia concludes.

Related Videos
Barbara Burtness, MD
Natalia Neparidze, MD
Arya Mariam Roy, MBBS
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD